Drug Trial Radar · NCT05417932
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Feb 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
46
Planned (sponsor's estimate)
Start
Oct 26, 2022
Primary completion
Sep 2025
Study completion Oct 2025
Sponsor
- Lead sponsor
- SCG Cell Therapy Pte. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1/ 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma
Conditions
- Hepatitis B Virus Related Hepatocellular Carcinoma
- Hepatocellular Carcinoma Recurrent
Interventions
SCG101Biological
Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of SCG101Time frame: Start of SCG101 infusion until 100 days post SCG101 infusion
- Tumor response of SCG101 (Phase 2)Time frame: Start of SCG101 infusion until a complate response or partial response is observed, disease progression, and long term survival follow up up to 15 years
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
New York
New York, New York · Recruiting
New York
New York, New York · Recruiting
Hong Kong is.
Hong Kong, Hong Kong · Not yet recruiting
Hong Kong NT
Hong Kong, Hong Kong · Recruiting
Singapore
Singapore, Singapore · Recruiting
Singapore
Singapore, Singapore · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.